{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:14:53Z","timestamp":1793661293964,"version":"4.5.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR21\/00026"],"award-info":[{"award-number":["JR21\/00026"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023961","name":"Centro de Investigaci\u00f3n Biotecnol\u00f3gica en Red de Enfermedades Infecciosas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023961","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FI23\/00074"],"award-info":[{"award-number":["FI23\/00074"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FI22\/00039"],"award-info":[{"award-number":["FI22\/00039"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013281","name":"Joint Programming Initiative on Antimicrobial Resistance","doi-asserted-by":"publisher","award":["AC22\/00032"],"award-info":[{"award-number":["AC22\/00032"]}],"id":[{"id":"10.13039\/100013281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PMP22\/00092"],"award-info":[{"award-number":["PMP22\/00092"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cmi.2025.03.013","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T09:30:26Z","timestamp":1742549426000},"page":"1790-1796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa"],"prefix":"10.1016","volume":"31","author":[{"given":"Antonio","family":"Oliver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Arca-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A.","family":"Gomis-Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.03.013_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.03.013_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.03.013_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.07.003","article-title":"WHO publishes updated list of bacterial priority pathogens","volume":"5","author":"Jesudason","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2025.03.013_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: Update from ESGARS-ESCMID\/ISARPAE Group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.03.013_bib5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.03.013_bib6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01942-24","article-title":"Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel \u03b2-lactams in Pseudomonas aeruginosa","volume":"69","author":"Sastre-Femenia","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jac\/dkn320","article-title":"NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106744","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021)","volume":"61","author":"Sader","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 7","key":"10.1016\/j.cmi.2025.03.013_bib11","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: Discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.03.013_bib12","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/jac\/dkae326","article-title":"Impact of transferable \u03b2-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa","volume":"79","author":"Gonz\u00e1lez-Pinto","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00517-17","article-title":"Evolved aztreonam resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa","volume":"8","author":"Jorth","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2025.03.013_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02529-16","article-title":"WCK 5107 (Zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent \"\u03b2-lactam enhancer\" activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-\u03b2-lactamase-producing high-risk clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106440","article-title":"In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates","volume":"58","author":"Meletiadis","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.03.013_bib17","article-title":"Impact of acquired broad spectrum \u03b2-lactamases on susceptibility to novel combinations made of \u03b2-lactams (aztreonam, cefepime, meropenem, and imipenem) and novel \u03b2-lactamase inhibitors in Escherichia coli and Pseudomonas aeruginosa","volume":"67","author":"Le Terrier","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.03.013_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01841-19","article-title":"A Standard numbering scheme for class C \u03b2-lactamases","volume":"64","author":"Mack","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/femsre\/fux043","article-title":"Diversity and regulation of intrinsic \u03b2-lactamases from non-fermenting and other gram-negative opportunistic pathogens","volume":"41","author":"Juan","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.03.013_bib21","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib22","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: Mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: Clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.03.013_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib25","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02085-18","article-title":"Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in Pseudomonas aeruginosa","volume":"9","author":"Barnes","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2025.03.013_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00894-20","article-title":"Adding insult to injury: Mechanistic basis for how AmpC mutations allow Pseudomonas aeruginosa to accelerate cephalosporin hydrolysis and evade avibactam","volume":"64","author":"Slater","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib28","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/jac\/dkad172","article-title":"In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa","volume":"78","author":"Gomis-Font","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.03.013_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.01512-08","article-title":"Diversity, epidemiology, and genetics of class D beta-lactamases","volume":"54","author":"Poirel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/dkaa396","article-title":"Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane\/tazobactam and ceftazidime\/avibactam during treatment of XDR Pseudomonas aeruginosa infections","volume":"76","author":"Arca-Su\u00e1rez","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106917","article-title":"Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa","volume":"62","author":"Vuillemin","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.03.013_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02496-17","article-title":"Molecular characterization of OXA-198 carbapenemase-producing Pseudomonas aeruginosa clinical isolates","volume":"62","author":"Bonnin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib34","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkac122","article-title":"Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial","volume":"77","author":"Torrens","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib35","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): A prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2025.03.013_bib36","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1128\/AAC.45.9.2598-2603.2001","article-title":"GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem","volume":"45","author":"Poirel","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib37","doi-asserted-by":"crossref","first-page":"29509","DOI":"10.1074\/jbc.M109.011262","article-title":"Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases","volume":"284","author":"Frase","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cmi.2025.03.013_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01164-24","article-title":"Mechanisms leading to in vivo ceftazidime\/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections","author":"Herrera","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib39","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 Mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01869-21","article-title":"Emergence of a KPC-90 variant that confers resistance to ceftazidime-avibactam in an ST463 carbapenem-resistant Pseudomonas aeruginosa strain","volume":"10","author":"Tu","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.03.013_bib41","doi-asserted-by":"crossref","first-page":"981792","DOI":"10.3389\/fcimb.2022.981792","article-title":"Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance","volume":"12","author":"Garc\u00eda","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2025.03.013_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria","volume":"28","author":"Li","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.03.013_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01379-18","article-title":"Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime-avibactam","volume":"62","author":"Sanz-Garc\u00eda","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib44","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/jac\/dkab213","article-title":"In vitro evolution of cefepime\/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy","volume":"76","author":"Barcel\u00f3","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib45","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1093\/jac\/dkaa206","article-title":"In vitro dynamics and mechanisms of resistance development to imipenem and imipenem\/relebactam in Pseudomonas aeruginosa","volume":"75","author":"Gomis-Font","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib46","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","author":"Shah","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.03.013_bib47","article-title":"Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: A nation-wide five-year time lapse analysis","volume":"34","author":"Sastre-Femenia","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cmi.2025.03.013_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00670-24","article-title":"Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021","volume":"68","author":"Li","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib49","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/cid\/ciac097","article-title":"Evolution of imipenem-relebactam resistance following treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia","volume":"75","author":"Shields","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.03.013_bib50","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/jac\/dkae263","article-title":"Impact of chromosomally encoded resistance mechanisms and transferable \u03b2-lactamases on the activity of cefiderocol and innovative \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa","volume":"79","author":"Gonz\u00e1lez-Pinto","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10096-023-04697-4","article-title":"Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain","volume":"43","author":"Hern\u00e1ndez-Garc\u00eda","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.03.013_bib52","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1365-2958.2002.03223.x","article-title":"On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: The large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition","volume":"46","author":"Mao","year":"2002","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cmi.2025.03.013_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00089-21","article-title":"Emergence of resistance to novel cephalosporin-\u03b2-lactamase inhibitor combinations through the modification of the Pseudomonas aeruginosa MexCD-OprJ efflux pump","volume":"65","author":"Gomis-Font","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib54","article-title":"Penicillin-binding protein 3 is essential for growth of Pseudomonas aeruginosa","volume":"61","author":"Chen","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib55","doi-asserted-by":"crossref","first-page":"22002","DOI":"10.1073\/pnas.1013092107","article-title":"Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa","volume":"107","author":"Han","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2025.03.013_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00981-15","article-title":"Selective sweeps and parallel pathoadaptation drive Pseudomonas aeruginosa. Evolution in the cystic fibrosis lung","volume":"6","author":"Diaz Caballero","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2025.03.013_bib57","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/jac\/dkae203","article-title":"Penicillin-binding protein 3 sequence variations reduce susceptibility of Pseudomonas aeruginosa to \u03b2-lactams but inhibit cell division","volume":"79","author":"Glen","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib58","article-title":"In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel \u03b2-lactam\/\u03b2-lactamase inhibitors","volume":"5","author":"Shields","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.03.013_bib59","article-title":"Emergence of cefiderocol resistance during ceftazidime\/avibactam treatment caused by a large genomic deletion, including ampD and piuCD genes","volume":"vol. 68","author":"Gomis-Font","year":"2024"},{"key":"10.1016\/j.cmi.2025.03.013_bib60","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/AAC.02676-15","article-title":"Evolution of Pseudomonas aeruginosa antimicrobial resistance and fitness under low and high mutation rates","volume":"60","author":"Cabot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.03.013_bib61","doi-asserted-by":"crossref","first-page":"9767","DOI":"10.1073\/pnas.1810004115","article-title":"Cellular hysteresis as a principle to maximize the efficacy of antibiotic therapy","volume":"115","author":"Roemhild","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2025.03.013_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005932","article-title":"CpxR Activates MexAB-OprM efflux pump expression and enhances antibiotic resistance in both laboratory and clinical nalB-type isolates of Pseudomonas aeruginosa","volume":"12","author":"Tian","year":"2016","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.cmi.2025.03.013_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106887","article-title":"Ceftolozane\/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity","volume":"62","author":"Agyeman","year":"2023","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25001314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25001314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:27:06Z","timestamp":1793503626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25001314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1198743X25001314"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.03.013","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}